Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 2.46
ANAC's Cash to Debt is ranked higher than
67% of the 1281 Companies
in the Global Biotechnology industry.

( Industry Median: 72.05 vs. ANAC: 2.46 )
ANAC' s 10-Year Cash to Debt Range
Min: 0.67   Max: No Debt
Current: 2.46

Equity to Asset 0.38
ANAC's Equity to Asset is ranked higher than
59% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. ANAC: 0.38 )
ANAC' s 10-Year Equity to Asset Range
Min: -6.53   Max: 0.71
Current: 0.38

-6.53
0.71
F-Score: 3
Z-Score: 8.79
M-Score: -0.54
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -438.92
ANAC's Operating margin (%) is ranked higher than
62% of the 1049 Companies
in the Global Biotechnology industry.

( Industry Median: -83.68 vs. ANAC: -438.92 )
ANAC' s 10-Year Operating margin (%) Range
Min: -15647.66   Max: 537.02
Current: -438.92

-15647.66
537.02
Net-margin (%) -421.28
ANAC's Net-margin (%) is ranked higher than
62% of the 1049 Companies
in the Global Biotechnology industry.

( Industry Median: -80.82 vs. ANAC: -421.28 )
ANAC' s 10-Year Net-margin (%) Range
Min: -15368.22   Max: 492.02
Current: -421.28

-15368.22
492.02
ROE (%) -95.96
ANAC's ROE (%) is ranked higher than
55% of the 1160 Companies
in the Global Biotechnology industry.

( Industry Median: -33.71 vs. ANAC: -95.96 )
ANAC' s 10-Year ROE (%) Range
Min: -599.54   Max: 134.29
Current: -95.96

-599.54
134.29
ROA (%) -52.22
ANAC's ROA (%) is ranked higher than
59% of the 1286 Companies
in the Global Biotechnology industry.

( Industry Median: -27.49 vs. ANAC: -52.22 )
ANAC' s 10-Year ROA (%) Range
Min: -216.67   Max: 75.94
Current: -52.22

-216.67
75.94
ROC (Joel Greenblatt) (%) -5737.87
ANAC's ROC (Joel Greenblatt) (%) is ranked higher than
57% of the 1251 Companies
in the Global Biotechnology industry.

( Industry Median: -373.92 vs. ANAC: -5737.87 )
ANAC' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -8736.49   Max: 6221.72
Current: -5737.87

-8736.49
6221.72
Revenue Growth (3Y)(%) -12.00
ANAC's Revenue Growth (3Y)(%) is ranked higher than
64% of the 723 Companies
in the Global Biotechnology industry.

( Industry Median: -0.80 vs. ANAC: -12.00 )
ANAC' s 10-Year Revenue Growth (3Y)(%) Range
Min: -70.5   Max: 467.9
Current: -12

-70.5
467.9
EBITDA Growth (3Y)(%) 10.60
ANAC's EBITDA Growth (3Y)(%) is ranked lower than
109% of the 749 Companies
in the Global Biotechnology industry.

( Industry Median: -7.20 vs. ANAC: 10.60 )
ANAC' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -63.1   Max: 10.6
Current: 10.6

-63.1
10.6
EPS Growth (3Y)(%) 6.40
ANAC's EPS Growth (3Y)(%) is ranked lower than
111% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -10.50 vs. ANAC: 6.40 )
ANAC' s 10-Year EPS Growth (3Y)(%) Range
Min: 0   Max: 6.4
Current: 6.4

0
6.4
» ANAC's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

ANAC Guru Trades in Q1 2014

Steven Cohen Sold Out
Jim Simons 32,700 sh (-69.09%)
» More
Q2 2014

ANAC Guru Trades in Q2 2014

Jim Simons 207,578 sh (+534.8%)
» More
Q3 2014

ANAC Guru Trades in Q3 2014

Chuck Royce 340,500 sh (New)
Steven Cohen 1,554,600 sh (New)
Jim Simons 109,358 sh (-47.32%)
» More
Q4 2014

ANAC Guru Trades in Q4 2014

Paul Tudor Jones 12,285 sh (New)
Steven Cohen 1,564,343 sh (+0.63%)
Chuck Royce 340,500 sh (unchged)
Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ANAC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 27.70
ANAC's P/B is ranked lower than
56% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 6.50 vs. ANAC: 27.70 )
ANAC' s 10-Year P/B Range
Min: 2.44   Max: 177.5
Current: 27.7

2.44
177.5
P/S 105.40
ANAC's P/S is ranked higher than
52% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 30.13 vs. ANAC: 105.40 )
ANAC' s 10-Year P/S Range
Min: 0.3   Max: 116.92
Current: 105.4

0.3
116.92
EV-to-EBIT -24.98
ANAC's EV-to-EBIT is ranked higher than
93% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ANAC: -24.98 )
ANAC' s 10-Year EV-to-EBIT Range
Min: -58.6   Max: 22.3
Current: -24.98

-58.6
22.3
Current Ratio 5.60
ANAC's Current Ratio is ranked higher than
80% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. ANAC: 5.60 )
ANAC' s 10-Year Current Ratio Range
Min: 1.18   Max: 9.58
Current: 5.6

1.18
9.58
Quick Ratio 5.52
ANAC's Quick Ratio is ranked higher than
81% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: 4.30 vs. ANAC: 5.52 )
ANAC' s 10-Year Quick Ratio Range
Min: 1.18   Max: 9.58
Current: 5.52

1.18
9.58
Days Inventory 355.75
ANAC's Days Inventory is ranked higher than
89% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ANAC: 355.75 )
ANAC' s 10-Year Days Inventory Range
Min: 576.58   Max: 576.58
Current: 355.75

Days Sales Outstanding 100.72
ANAC's Days Sales Outstanding is ranked higher than
90% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 112.01 vs. ANAC: 100.72 )
ANAC' s 10-Year Days Sales Outstanding Range
Min: 1.43   Max: 365
Current: 100.72

1.43
365

Valuation & Return

vs
industry
vs
history
Price/Net Cash 129.20
ANAC's Price/Net Cash is ranked higher than
62% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 93.33 vs. ANAC: 129.20 )
ANAC' s 10-Year Price/Net Cash Range
Min: 2.95   Max: 80.63
Current: 129.2

2.95
80.63
Price/Net Current Asset Value 97.50
ANAC's Price/Net Current Asset Value is ranked higher than
59% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 39.86 vs. ANAC: 97.50 )
ANAC' s 10-Year Price/Net Current Asset Value Range
Min: 2.8   Max: 57.78
Current: 97.5

2.8
57.78
Price/Tangible Book 28.10
ANAC's Price/Tangible Book is ranked lower than
55% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 10.00 vs. ANAC: 28.10 )
ANAC' s 10-Year Price/Tangible Book Range
Min: 2.67   Max: 93.17
Current: 28.1

2.67
93.17
Price/Median PS Value 6.30
ANAC's Price/Median PS Value is ranked higher than
63% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 2.90 vs. ANAC: 6.30 )
ANAC' s 10-Year Price/Median PS Value Range
Min: 0.02   Max: 3.96
Current: 6.3

0.02
3.96
Earnings Yield (Greenblatt) -4.00
ANAC's Earnings Yield (Greenblatt) is ranked higher than
91% of the 1264 Companies
in the Global Biotechnology industry.

( Industry Median: -5.00 vs. ANAC: -4.00 )
ANAC' s 10-Year Earnings Yield (Greenblatt) Range
Min: -4.2   Max: 18.9
Current: -4

-4.2
18.9

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:44A.Germany,
Anacor Pharmaceuticals Inc was incorporated in Delaware in December 2000 and began business operations in March 2002. It is a biopharmaceutical company engaged in discovering, developing and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. It has discovered, synthesized and developed eight molecules that are currently in development. The Company's main product candidates include two topically administered dermatologic compounds, tavaborole (formerly referred to as AN2690) and AN2728. Tavaborole is a topical treatment for onychomycosis, a fungal infection of the nail and nail bed. AN2728 is its main topical anti-inflammatory product candidate for the treatment of atopic dermatitis and psoriasis, chronic inflammatory skin diseases that affect millions of people. In addition, the Company has three other wholly-owned clinical product candidates; AN2718 and AN2898, which are backup compounds to tavaborole and AN2728, respectively, and AN3365 (formerly referred to as GSK2251052, or GSK '052), an antibiotic for the treatment of infections caused by Gram-negative bacteria, which previously was licensed to GlaxoSmithKline LLC (GSK). It has also discovered three other compounds that it has out-licensed for further development; one is licensed to Eli Lilly and Company (Lilly), for the treatment of an animal health indication; a second compound, AN5568, also referred to as SCYX-7158, is licensed to Drugs for Neglected Diseases initiative (DNDi), for human African trypanosomiasis (HAT, or sleeping sickness); and a third compound is licensed to GSK for tuberculosis (TB). As of February 1, 2014, the company was the owner of record, either solely or with a collaborator, of 23 issued U.S. patents. The Company and its third-party manufacturers are subject to periodic inspections of facilities by the FDA and other authorities, including procedures and operations used in the testing and manufacture of its products to assess its compliance with applicable regulations.
» More Articles for ANAC

Headlines

Articles On GuruFocus.com
Anacor Pharmaceuticals’ Q4 Was A Solid One For Investors Mar 16 2015 
Paulson Bets Again On Mallinckrodt Aug 07 2014 
3 Great Dividend Stocks at All-Time Highs Aug 19 2013 
Weekly CFO Buys Highlight Aug 19 2013 
Senior Vice President and CFO of Anacor Pharmaceuticals Inc. Geoffrey Parker Bought 43,046 Shares Jun 20 2013 
This Week's Top Insider Buys Jun 19 2013 
comment on ANAC Mar 16 2013 
Weekly CFO Buys Highlight: SSP, BMTI, POL, ANAC, CYTX Mar 26 2012 
Weekly CFO Buys Highlight: GSVC, SHO, YAVY, CMCSA, ANAC May 16 2011 

More From Other Websites
Abercrombie & Fitch Co., Anacor Pharmaceuticals Inc and Civeo Corp (CVEO): Latest Insider Action Mar 26 2015
Nasdaq stocks posting largest percentage increases Mar 26 2015
ANACOR PHARMACEUTICALS, INC. Files SEC form 10-K, Annual Report Mar 16 2015
Company News for March 16, 2015 - Corporate Summary Mar 16 2015
Anacor Pharmaceuticals hits record high on earnings Mar 13 2015
Anacor Pharmaceuticals Reports 2014 Fourth Quarter and Year-End Financial Results Mar 13 2015
Anacor reports 4Q loss Mar 12 2015
Anacor reports 4Q loss Mar 12 2015
Anacor Pharmaceuticals Announces Presentations at the American Academy of Dermatology Annual Meeting Mar 12 2015
ANACOR PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Mar 12 2015
Anacor Pharmaceuticals Announces Presentations at the American Academy of Dermatology Annual Meeting Mar 12 2015
Anacor Pharmaceuticals Reports 2014 Fourth Quarter and Year-End Financial Results Mar 12 2015
Anacor Pharmaceuticals Announces 2014 Fourth Quarter and Year-End Financial Results Conference Call... Mar 05 2015
Anacor Pharmaceuticals Announces 2014 Fourth Quarter and Year-End Financial Results Conference Call... Mar 05 2015
Juno Therapeutics Inc (JUNO), Anacor Pharmaceuticals Inc (ANAC): VHCP Management’s Top 3 Biotech... Mar 02 2015
Anacor Pharmaceuticals to Present at the 35th Annual Cowen Health Care Conference Feb 26 2015
Anacor Pharmaceuticals to Present at the 35th Annual Cowen Health Care Conference Feb 25 2015
Can The Uptrend Continue for Anacor (ANAC)? - Tale of the Tape Jan 29 2015
Symbiota Names Entrepreneurial Leader David P. Perry as President and CEO Jan 07 2015
ANACOR PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report Nov 07 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK